MedTrace Logo

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

NCT01582451 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 466

Last updated 2018-04-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare LY2605541 and insulin glargine using the following measures after participants have been treated for 26 weeks:

* Change in participants' overall blood sugar control
* The rate of night time low blood sugar episodes
* The number of participants that reach blood sugar targets without low blood sugar episodes at night
* The rate of low blood sugar episodes reported over a 24-hour period

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

LY2605541

DRUG

Insulin glargine

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2013-05-31
Completion
2013-12-31

Countries

  • United States
  • Czechia
  • Germany
  • Greece
  • Israel
  • Puerto Rico
  • Romania
  • Russia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01582451 on ClinicalTrials.gov